Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Autor: Ito, Kiyomi, Chiba, Koji, Horikawa, Masato, Ishigami, Michi, Mizuno, Naomi, Aoki, Jun, Gotoh, Yasumasa, Iwatsubo, Takafumi, Kanamitsu, Shin-ichi, Kato, Motohiro, Kawahara, Iichiro, Niinuma, Kayoko, Nishino, Akiko, Sato, Norihito, Tsukamoto, Yuko, Ueda, Kaoru, Itoh, Tomoo, Sugiyama, Yuichi

Publikováno v: AAPS Journal; Dec2002, Vol. 4 Issue 4, p53-60, 8p

[High throughput screening of pharmacokinetics and metabolism in drug discovery (III)--investigation on in- silico model for membrane permeability and CYP1A2 inhibition].

Autor: Komura H; Department of Research Pharmacokinetics, Research Center Kyoto, Bayer Yakuhin, Ltd., Kyoto 619-0216, Japan. hiroshi.komura.hk@bayer.co.jp, Shigemoto Y, Kawahara I, Matsuda K, Ano R, Murayama Y, Moriwaki T, Yoshida NH

Publikováno v: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan [Yakugaku Zasshi] 2005 Jan; Vol. 125 (1), pp. 141-7.

[High throughput screening of pharmacokinetics and metabolism in drug discovery (II)--investigation on in vitro and in vivo correlation in drug metabolism screening].

Autor: Komura H; Department of Research Pharmacokinetics, Research Center Kyoto, Bayer Yakuhin, Ltd., Kyoto 619-0216, Japan. hiroshi.komura.hk@bayer.co.jp, Matsuda K, Shigemoto Y, Kawahara I, Ano R, Murayama Y, Moriwaki T, Yoshida NH

Publikováno v: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan [Yakugaku Zasshi] 2005 Jan; Vol. 125 (1), pp. 131-9.